1. Home
  2. PDX vs ELVN Comparison

PDX vs ELVN Comparison

Compare PDX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PDX

PIMCO Dynamic Income Strategy Fund of Beneficial Interest

HOLD

Current Price

$21.59

Market Cap

996.5M

Sector

Finance

ML Signal

HOLD

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

HOLD

Current Price

$19.90

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDX
ELVN
Founded
2019
2016
Country
NY
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
996.5M
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PDX
ELVN
Price
$21.59
$19.90
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$41.20
AVG Volume (30 Days)
N/A
641.0K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
4.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$20.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.52
$13.30
52 Week High
$21.05
$25.96

Technical Indicators

Market Signals
Indicator
PDX
ELVN
Relative Strength Index (RSI) 43.99 43.57
Support Level $21.11 $21.05
Resistance Level $21.98 $22.14
Average True Range (ATR) 0.38 1.38
MACD 0.06 -0.04
Stochastic Oscillator 58.10 27.72

Price Performance

Historical Comparison
PDX
ELVN

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Share on Social Networks: